Fluxion Biosciences Awarded NIH Grant for Development of High Throughput Screening...

Fluxion Biosciences Awarded NIH Grant for Development of High Throughput Screening Platform

Microfluidic Design Enables High-Throughput Anti-microbial
Screening
SAN FRANCISCO--(Business Wire)--
Fluxion Biosciences, a leading developer of microfluidic systems
for cellular analysis in life sciences research, today announced that
it has received an NIH grant for the development of a high throughput
screening platform for anti-microbial drug discovery. The Phase I NIH
grant will enable the Company to further develop its innovative
microfluidic platform for cellular research and drug discovery.

Anti-microbial drugs such as penicillin, tetracycline, and
amoxicillin have been around for decades. Over time, certain microbes
have developed resistance to these treatments. Drug-resistant
infections cause 14,000 deaths in America each year, and add over $4B
in cost to the healthcare system. The newly awarded grant is focused
on the development of a higher throughput microfluidic system for
anti-microbial drug discovery and development. The principal aims of
the grant include novel detection methods for anti-microbial
effectiveness and systems for conducting multi-point dose response
curves.

"We are excited to receive this NIH grant for the continued
development of our microfluidic technology," said Carolyn Conant,
Ph.D., Project Leader for the grant. "The ability to rapidly screen
and characterize anti-microbial compounds will be a powerful tool for
developing the next generation of drug therapies."

About Fluxion Biosciences

Fluxion Biosciences develops cellular analysis tools for use in
critical applications in life sciences research and drug discovery.
Fluxion's proprietary microfluidic platform, CellFlux, enables precise
functional analysis of individual cells in a highly multiplexed
format. Products include the BioFlux System for biofilm and cellular
adhesion assays, IonFlux System for cellular electrophysiology, and
the CytoFlux System for stop-flow imaging cytometry. These products
meet the rigorous demands of life science and drug discovery
scientists by providing an intuitive, easy-to-use "operating system"
for single-cell biology. For more information about Fluxion
Biosciences, visit www.fluxionbio.com.

Fluxion Biosciences
Jeff Jensen, CEO, 925-518-7046
jeff.jensen@fluxionbio.com

Copyright Business Wire 2008